Given that the prognostic and predictive role of KRAS-LCS6 polymorphism was not yet investigated in lung cancer, we planned an ancillary study to assess the value of KRAS-LCS6 polymorphism on outcomes within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line NSCLC. Here, KRAS is linked to lung cancer.